Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.
Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H; PROUD-PV Study Group. Kiladjian JJ, et al. Among authors: krochmalczyk d. Leukemia. 2022 May;36(5):1408-1411. doi: 10.1038/s41375-022-01528-x. Epub 2022 Feb 24. Leukemia. 2022. PMID: 35210530 Free PMC article. No abstract available.
Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: krochmalczyk d. Leukemia. 2023 Oct;37(10):2129-2132. doi: 10.1038/s41375-023-02008-6. Epub 2023 Aug 26. Leukemia. 2023. PMID: 37634011 Free PMC article. No abstract available.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Sobas M, et al. Among authors: krochmalczyk d. Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201. Blood Adv. 2022. PMID: 35802458 Free PMC article.
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Hasselbalch HC, Kralovics R, Kiladjian JJ. Gisslinger H, et al. Among authors: krochmalczyk d. Hemasphere. 2020 Oct 20;4(6):e485. doi: 10.1097/HS9.0000000000000485. eCollection 2020 Dec. Hemasphere. 2020. PMID: 33134869 Free PMC article. No abstract available.
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group. Gisslinger H, et al. Among authors: krochmalczyk d. Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Lancet Haematol. 2020. PMID: 32014125 Clinical Trial.
Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis.
Wołowiec D, Szymczyk A, Potoczek S, Krochmalczyk D, Zawirska D, Piotrowska M, Malenda A, Soroka-Wojtaszko M, Kopacz A, Wąsik-Szczepanek E, Graboś-Michalak J, Raźny M, Wichary R, Bramowicz-Jarosz B, Seweryn M, Długosz-Danecka M, Hus I. Wołowiec D, et al. Among authors: krochmalczyk d. Chemotherapy. 2019;64(3):155-162. doi: 10.1159/000503220. Epub 2019 Nov 12. Chemotherapy. 2019. PMID: 31715597
Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K, Lis K, Biecek P, Młynarczyk M, Rytel J, Górka M, Kacprzyk P, Dutka M, Rodzaj M, Bołkun Ł, Krochmalczyk D, Łątka E, Drozd-Sokołowska J, Waszczuk-Gajda A, Knopińska-Posłuszny W, Kopińska A, Subocz E, Masternak A, Guzicka-Kazimierczak R, Gil L, Machowicz R, Biliński J, Giebel S, Czerw T, Dwilewicz-Trojaczek J. Mądry K, et al. Among authors: krochmalczyk d. Clin Lymphoma Myeloma Leuk. 2019 May;19(5):264-274.e4. doi: 10.1016/j.clml.2019.01.002. Epub 2019 Jan 23. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30898482
11 results